Vertex Pharmaceuticals EVP, Global Research and CSO David Altshuler Sells 4,002 Shares
David Altshuler, EVP, Global Research and CSO of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), sold 4,002 shares of the company on February 20, 2024, according to a recent SEC filing. The transaction was executed at an average price of $420.79 per share, resulting in a total value of $1,684,041.58.
Vertex Pharmaceuticals Inc is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has a portfolio of products and a robust pipeline of investigational drugs designed to treat cystic fibrosis and other serious diseases.
Over the past year, the insider has sold a total of 11,231 shares of Vertex Pharmaceuticals Inc and has not made any purchases of the stock. The insider transaction history for the company shows a total of 60 insider sells and no insider buys over the past year.
Shares of Vertex Pharmaceuticals Inc were trading at $420.79 on the day of the insider's recent sale, giving the company a market cap of $108.39 billion. The price-earnings ratio of the stock is 30.21, which is higher than the industry median of 29.38 and also above the company's historical median price-earnings ratio.
With the current share price and a GuruFocus Value of $349.20, Vertex Pharmaceuticals Inc has a price-to-GF-Value ratio of 1.21, indicating that the stock is Modestly Overvalued according to the GF Value metric.
The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on the company's past returns and growth, and future business performance estimates from Morningstar analysts.
The insider trend image above reflects the recent insider selling activity at Vertex Pharmaceuticals Inc.
The GF Value image above provides an intrinsic value estimate for Vertex Pharmaceuticals Inc, suggesting the stock's current valuation status.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
